{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:19:21Z","timestamp":1790813961705,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.neurol.2023.03.013","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T07:52:27Z","timestamp":1681458747000},"page":"430-436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Overcoming the blood brain barrier in glioblastoma: Status and future perspective"],"prefix":"10.1016","volume":"179","author":[{"given":"M.H.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Canney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Carpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Idbaih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2023.03.013_bib0205","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurol.2023.03.013_bib0210","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.neurol.2023.03.013_bib0215","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2023.03.013_bib0220","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurol.2023.03.013_bib0225","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurol.2023.03.013_bib0230","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11060-020-03408-9","article-title":"Convection-enhanced drug delivery for glioblastoma: a review","volume":"151","author":"D\u2019Amico","year":"2021","journal-title":"J Neurooncol"},{"key":"10.1016\/j.neurol.2023.03.013_bib0235","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1080\/14737175.2016.1202761","article-title":"Blood-brain barrier, cytotoxic chemotherapies and glioblastoma","volume":"16","author":"Dr\u00e9an","year":"2016","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.neurol.2023.03.013_bib0240","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/neuonc\/nov164","article-title":"Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma","volume":"18","author":"Oberoi","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurol.2023.03.013_bib0245","doi-asserted-by":"crossref","first-page":"7723","DOI":"10.1038\/s41598-022-11172-1","article-title":"Daily blood pressure profile and blood-brain barrier permeability in patients with cerebral small vessel disease","volume":"12","author":"Dobrynina","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurol.2023.03.013_bib0250","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12885-016-2311-4","article-title":"High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma-a randomized phase III trial (MATRix)","volume":"16","author":"Schorb","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.neurol.2023.03.013_bib0255","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1200\/EDBK_200829","article-title":"Treatment of primary central nervous system lymphoma: from chemotherapy to small molecules","author":"Mendez","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.neurol.2023.03.013_bib0260","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1038\/s41598-020-80724-0","article-title":"High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials","volume":"11","author":"Yu","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurol.2023.03.013_bib0265","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neurol.2023.03.013_bib0270","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/A:1006457502972","article-title":"Randomized comparison of intra-arterial versus intravenous infusion of ACNU for newly diagnosed patients with glioblastoma","volume":"49","author":"Kochii","year":"2000","journal-title":"J Neurooncol"},{"key":"10.1016\/j.neurol.2023.03.013_bib0275","first-page":"553","article-title":"A randomized phase III study: comparison between intravenous and intraarterial ACNU administration in newly diagnosed primary glioblastomas","volume":"26","author":"Imbesi","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.neurol.2023.03.013_bib0280","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3390\/pharmaceutics11050248","article-title":"Drug delivery technology to the CNS in the treatment of brain tumors: the sherbrooke experience","volume":"11","author":"Fortin","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.neurol.2023.03.013_bib0285","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3389\/fonc.2019.00966","article-title":"Convection-enhanced delivery: connection to and impact of interstitial fluid flow","volume":"9","author":"Stine","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.neurol.2023.03.013_bib0290","doi-asserted-by":"crossref","first-page":"4047617","DOI":"10.1155\/2019\/4047617","article-title":"Complications of intrathecal chemotherapy in adults: single-institution experience in 109 consecutive patients","volume":"2019","author":"Byrnes","year":"2019","journal-title":"J Oncol"},{"key":"10.1016\/j.neurol.2023.03.013_bib0295","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000441380","article-title":"Two fatal cases of accidental intrathecal vincristine administration: learning from death events","volume":"61","author":"Chotsampancharoen","year":"2016","journal-title":"Chemotherapy"},{"key":"10.1016\/j.neurol.2023.03.013_bib0300","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.addr.2020.02.006","article-title":"Intrathecal drug delivery in the era of nanomedicine","volume":"165-166","author":"Fowler","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.neurol.2023.03.013_bib0305","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/neuonc\/nop054","article-title":"Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma","volume":"12","author":"Kunwar","year":"2010","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurol.2023.03.013_bib0310","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.3390\/cancers14215341","article-title":"Medical device advances in the treatment of glioblastoma","volume":"14","author":"Foo","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.neurol.2023.03.013_bib0315","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.actbio.2020.11.030","article-title":"Biocompatible copolymer formulations to treat glioblastoma multiforme","volume":"121","author":"Erthal","year":"2021","journal-title":"Acta Biomater"},{"key":"10.1016\/j.neurol.2023.03.013_bib0320","doi-asserted-by":"crossref","first-page":"705886","DOI":"10.3389\/fbioe.2021.705886","article-title":"Liposomes: structure, Biomedical applications, and stability parameters with emphasis on cholesterol","volume":"9","author":"Nakhaei","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.neurol.2023.03.013_bib0325","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jocn.2011.02.026","article-title":"Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy","volume":"18","author":"Ananda","year":"2011","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.neurol.2023.03.013_bib0330","series-title":"Glioblastoma resistance to chemotherapy: molecular mechanisms and innovative reversal strategies","first-page":"243","article-title":"Chapter 9 - Role of multidrug resistance in glioblastoma chemoresistance: Focus on ABC transporters","author":"Ahmed M","year":"2021"},{"key":"10.1016\/j.neurol.2023.03.013_bib0335","series-title":"225antiseizure medications in patients with brain tumors. Antiseizure medications: a clinician's manual","first-page":"p0","author":"Asadi-Pooya","year":"2022"},{"key":"10.1016\/j.neurol.2023.03.013_bib0340","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.eplepsyres.2014.08.009","article-title":"A pilot double-blind trial using verapamil as adjuvant therapy for refractory seizures","volume":"108","author":"Borlot","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.neurol.2023.03.013_bib0345","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1021\/acsmedchemlett.6b00005","article-title":"Discovery of clinical development candidate GDC-0084, a brain penetrant inhibitor of PI3K and mTOR","volume":"7","author":"Heffron","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.neurol.2023.03.013_bib0350","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/neuonc\/5.2.96","article-title":"A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma","volume":"5","author":"Prados","year":"2003","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurol.2023.03.013_bib0355","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1158\/1541-7786.MCR-19-0995","article-title":"Adenosine A2A receptor activation enhances blood-tumor barrier permeability in a rodent glioma model","volume":"19","author":"V\u00e9zina","year":"2021","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.neurol.2023.03.013_bib0360","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12987-017-0088-8","article-title":"The effect of an adenosine A(2A) agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma","volume":"15","author":"Jackson","year":"2018","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.neurol.2023.03.013_bib0365","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000120809","article-title":"Therapeutic dilemma of disseminated CNS germinoma and the potential of increased platinum-based chemotherapy delivery with osmotic blood-brain barrier disruption","volume":"21","author":"Neuwelt","year":"1994","journal-title":"Pediatr Neurosurg"},{"key":"10.1016\/j.neurol.2023.03.013_bib0370","doi-asserted-by":"crossref","first-page":"343re2","DOI":"10.1126\/scitranslmed.aaf6086","article-title":"Clinical trial of blood-brain barrier disruption by pulsed ultrasound","volume":"8","author":"Carpentier","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.neurol.2023.03.013_bib0375","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1158\/1078-0432.CCR-18-3643","article-title":"Safety and feasibility of repeated and transient blood-brain barrier disruption by pulsed ultrasound in patients with recurrent glioblastoma","volume":"25","author":"Idbaih","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neurol.2023.03.013_bib0380","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41598-018-36340-0","article-title":"Blood-brain barrier opening in primary brain tumors with non-invasive MR-guided focused ultrasound: a clinical safety and feasibility study","volume":"9","author":"Mainprize","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurol.2023.03.013_bib0385","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noac174.137","article-title":"Implantable electrophoretic devices for local treatment of inoperable brain tumours","author":"Ahmed","year":"2022","journal-title":"Neuro Oncology"},{"key":"10.1016\/j.neurol.2023.03.013_bib0390","doi-asserted-by":"crossref","first-page":"213102","DOI":"10.1016\/j.bioadv.2022.213102","article-title":"Enhanced delivery to brain using sonosensitive liposome and microbubble with focused ultrasound","volume":"141","author":"Moon","year":"2022","journal-title":"Biomater Adv"},{"key":"10.1016\/j.neurol.2023.03.013_bib0395","doi-asserted-by":"crossref","first-page":"125","DOI":"10.7150\/ntno.52168","article-title":"MR-labelled liposomes and focused ultrasound for spatiotemporally controlled drug release in triple negative breast cancers in mice","volume":"5","author":"Amrahli","year":"2021","journal-title":"Nanotheranostics"},{"key":"10.1016\/j.neurol.2023.03.013_bib0400","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3390\/ijms24010825","article-title":"Sonosensitive phase-changeable nanoparticle mediated enhanced chemotherapy in prostate cancer by low-intensity focused ultrasound","volume":"24","author":"Dai","year":"2023","journal-title":"Int J Mol Sci"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378723008950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378723008950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:46:23Z","timestamp":1758519983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378723008950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0035378723008950"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2023.03.013","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming the blood brain barrier in glioblastoma: Status and future perspective","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2023.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}